Date: 2016-09-29
Type of information: Licensing agreement
Compound: RNA interference (RNAi) therapies for cardiovascular disease including RNAi ARC-LPA program
Company: Amgen (USA - CA) Arrowhead Pharmaceuticals (USA - CA)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing development commercialisation
Action mechanism: RNAi.
Disease:
Details: * On September 29, 2016, Amgen and Arrowhead Pharmaceuticals announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowhead's proprietary subcutaneous RNAi delivery platform.
Under one agreement, Amgen receives a worldwide, exclusive license to Arrowhead's novel, RNAi ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the second agreement, Amgen receives an option to a worldwide, exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen will be wholly responsible for clinical development and commercialization.
Financial terms: Under the terms of the agreements taken together, Arrowhead will receive $35 million in upfront payments; $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock; and up to $617 million in option payments, and development, regulatory and sales milestone payments. Arrowhead is further eligible to receive single digit royalties for sales of products against the undisclosed target and up to low double digit royalties for sales of products under the ARC-LPA agreement. Additional financial terms of the agreements are not disclosed.
Latest news:
